Trial Profile
A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 1959 Following a Single Subcutaneous Administration in Japanese Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 09 Dec 2017 Results assessing safety and efficacy of Guselkumab in Japanese patients published in the British Journal of Dermatology
- 06 Dec 2011 New trial record